While Novo Nordisk and Lilly seem best positioned now, emerging agents, oral options, dual/triple agonist molecules may capture niches or even displace certain uses of the first wave of GLP-1s
And we are working so hard to develop a study ourselves, just really looking at more progressive, because so much of the studies that involve, you know, combo [01:04:00] use or active thyroid hormone use are executed so poorly and done so, so poorly that they don't show a significant difference in how people feel
Eng modified and purified exendin-4 into a drug form called exenatide, which became the first GLP-1 medication: Byetta (approved in 2005)
Biology 14(7):803 Abedpoor N, Taghian F, Jalali Dehkordi K, Safavi K (2024) Sparassis latifolia and exercise training as complementary medicine mitigated the 5-fluorouracil potent side effects in mice with colorectal cancer: bioinformatics approaches, novel monitoring pathological metrics, screening signatures, and innovative management tactic